XML 36 R23.htm IDEA: XBRL DOCUMENT v3.21.1
The Company and Summary of Significant Accounting Policies - Additional Information (Detail)
 3 Months Ended 9 Months Ended
Mar. 31, 2021
USD ($)
Mar. 31, 2020
USD ($)
Mar. 31, 2021
USD ($)
ClinicalTrials
Mar. 31, 2020
USD ($)
Jun. 30, 2020
USD ($)
Jun. 30, 2019
USD ($)
Targeted or Tracking Stock, Stock [Line Items]            
Number of clinical stage candidates | ClinicalTrials     4      
Deferred Revenue Associated With Remaining Performance Obligation $ 89,900,000   $ 89,900,000      
Unrecognized tax benefits 0   0   $ 0  
Revenue Recognised With Performance Obligation 2,300,000 $ 800,000 15,000,000 $ 2,300,000    
Accumulated Losses Since Inception (322,093,000)   (322,093,000)   (277,234,000)  
Cash And Cash Equivalents,Short Term Investments And Common Stock Proceeds Receivable 164,600,000   164,600,000      
Contract assets, Current 7,432,000 353,000 7,432,000 353,000 $ 335,000 $ 511,000
Increase (Decrease) in Deferred Revenue (2,100,000)   7,377,000 (2,479,000)    
US License            
Targeted or Tracking Stock, Stock [Line Items]            
Deferred Revenue Associated With Remaining Performance Obligation 64,500,000   64,500,000      
Ex US License            
Targeted or Tracking Stock, Stock [Line Items]            
Deferred Revenue Associated With Remaining Performance Obligation 25,400,000   25,400,000      
Helsinn License Agreement            
Targeted or Tracking Stock, Stock [Line Items]            
Deferred Revenue, Revenue Recognized 100,000 400,000 400,000 1,100,000    
KKC Commercialization Agreement And The Helsinn License Agreement            
Targeted or Tracking Stock, Stock [Line Items]            
Contract assets, Current 7,400,000   7,400,000      
Increase in contract assets     22,800,000      
KKC Agreements and Helsinn License Agreement            
Targeted or Tracking Stock, Stock [Line Items]            
Contract with Customer, Liability, Revenue Recognized $ 2,400,000 $ 800,000 $ 15,400,000 $ 2,600,000